论文部分内容阅读
目的研究培美曲塞联合顺铂与(紫杉醇、吉西他滨或长春瑞滨)联合顺铂组治疗晚期非小细胞肺癌的疗效及不良反应对比。方法 36例晚期非小细胞肺癌患者,分为两组每组18例,一组给予培美曲塞联合顺铂全身化疗,另一组给予(紫杉醇、吉西他滨或长春瑞滨)联合顺铂全身化疗。结果实验组完全缓解(CR)0例,部分缓解(PR)4例,稳定(SD)10例,进展(PD)4例,总有效率(CR+PR)为22.2%,疾病控制率(CR+PR+SD)为77.8%;对照组完全缓解(CR)0例,部分缓解(PR)3例,稳定(SD)9例,进展(PD)6例,总有效率(CR+PR)为16.7%,疾病控制率(CR+PR+SD)为66.7%。两组相比差异无统计学意义(P>0.05)。TTP和OS差异无统计学意义,但在血液毒性及消化道反应方面,实验组低于对照组。结论培美曲塞联合顺铂一线治疗晚期非小细胞肺癌具有有效、毒性低,且具有较好的耐受性。
Objective To study the efficacy and side effects of pemetrexed combined with cisplatin (paclitaxel, gemcitabine or vinorelbine) and cisplatin in the treatment of advanced non-small cell lung cancer. Methods Thirty - six patients with advanced non - small cell lung cancer were divided into two groups of 18 patients in each group. One group received systemic chemotherapy with pemetrexed combined with cisplatin, and the other group with paclitaxel, gemcitabine or vinorelbine combined with cisplatin . Results In the experimental group, there were 0 cases of complete remission (CR), 4 cases of partial remission (PR), 10 cases of stable (SD) and 4 cases of progression (PD). The total effective rate was 22.2% (PR + SD + PR + SD) was 77.8%. There were 0 complete remission (CR), 3 partial remission (PR), 9 stable (SD) and 6 progressive (PD) 16.7%, disease control rate (CR + PR + SD) was 66.7%. There was no significant difference between the two groups (P> 0.05). TTP and OS differences were not statistically significant, but in the hematotoxicity and gastrointestinal reactions, the experimental group was lower than the control group. Conclusions Pemetrexed combined with cisplatin in the treatment of advanced non-small cell lung cancer is effective, less toxic and more tolerable.